Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Toxicologic Pathology|August 22, 2002
Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterationsHisham K Hamadeh, Brian L Knight, Astrid C Haugen, et al.Environmental Health Perspectives|March 23, 2004
Identification of platform-independent gene expression markers of cisplatin nephrotoxicityKarol L Thompson, Cynthia A Afshari, Rupesh P Amin, et al.Toxicologic Pathology|April 20, 2023
Early-Onset albuminuria and Associated Renal Pathology in Leucine-Rich Repeat Kinase 2 Knockout RatsYi-Zhong Gu, Katerina Vlasakova, Glen Miller, et al.Environmental Health Perspectives|March 23, 2004
Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessmentJeffrey A Kramer, Syril D Pettit, Rupesh P Amin, et al.Toxicological Sciences : an Official Journal of the Society of Toxicology|December 13, 2021
Guiding Chemically Synthesized Peptide Drug Lead Optimization by Derisking Mast Cell Degranulation-Related Toxicities of a NaV1.7 Peptide InhibitorPierre Morissette, Nianyu Li, Jeanine E Ballard, et al.Environmental Health Perspectives|March 23, 2004
Identification of putative gene based markers of renal toxicityRupesh P Amin, Alison E Vickers, Frank Sistare, et al.Journal of Medicinal Chemistry|March 29, 2022
Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early DiscoveryMihirbaran Mandal, Maria Madeira, Rupesh P Amin, et al.Journal of Medicinal Chemistry|November 10, 2020
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based DesignCandice Alleyne, Rupesh P Amin, Bhavana Bhatt, et al.Bioorganic & Medicinal Chemistry Letters|October 13, 2024
Discovery of sulfone containing metallo-β-lactamase inhibitors with reduced bacterial cell efflux and histamine release issuesFrank Bennett, Yuhua Huang, Shuzhi Dong, et al.Journal of Medicinal Chemistry|October 27, 2021
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 InhibitorsThomas J Tucker, Mark W Embrey, Candice Alleyne, et al.Pageof 3